The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
CAR-T therapy in solid tumors
Abstract
While chimeric antigen receptor (CAR) T cell therapy has shown great success in hematologic malignancies, the effectiveness in solid tumors has been limited by several factors, including antigenic heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). In this review, we discuss the advancements made in clinical studies and challenges faced by CAR-T therapy for solid tumors. To enhance CAR-T cell efficacy in solid tumors, we explore strategies such as enhancing T cell persistence and cytotoxicity, targeting multiple antigens, and utilizing innovative allogeneic CAR-T cell manufacturing. Additionally, we highlight the potential benefits of combining CAR-T therapies with immune checkpoint inhibitors and other treatment modalities to overcome TME limitations. We remain optimistic about the future of CAR-T cell therapy in solid tumors, emphasizing the need for continued research to refine therapeutic approaches and address the clinical needs of patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Melenhorst, J. J., Chen, G. M., Wang, M., Porter, D. L., Chen, C., Collins, M. A., Gao, P., Bandyopadhyay, S., Sun, H., Zhao, Z., et al. (2022) · Nature · doi:10.1038/s41586-021-04390-6 · Cited by 923
c-Jun overexpression in CAR T cells induces exhaustion resistance
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891
NR4A transcription factors limit CAR T cell function in solid tumours
Chen, J., López-Moyado, I. F., Seo, H., Lio, C.-W. J., Hempleman, L. J., Sekiya, T., Yoshimura, A., Scott-Browne, J. P., & Rao, A. (2019) · Nature · doi:10.1038/s41586-019-0985-x · Cited by 874
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., et al. (2022) · Nature · doi:10.1038/s41586-022-04489-4 · Cited by 823
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M. M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 814
Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792
Cho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Sterner, R. M., Sakemura, R., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881722 · Cited by 621
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Daniel, B., Klysz, D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 607
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., Mastronuzzi, A., Cefalo, M. G., Pagliara, D., Amicucci, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2210859 · Cited by 561
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou-el-Enein, M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 554
Narayan, V., Barber-Rotenberg, J. S., Jung, I.-Y., Lacey, S. F., Rech, A. J., Davis, M. M., Hwang, W.-T., Lal, P., Carpenter, E. L., Maude, S. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01726-1 · Cited by 533
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Reinhard, K., Rengstl, B., Oehm, P., Michel, K., Billmeier, A., Hayduk, N., Klein, O., Kuna, K., Ouchan, Y., Wöll, S., et al. (2020) · Science · doi:10.1126/science.aay5967 · Cited by 512
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
Choi, B. D., Gerstner, E. R., Frigault, M. J., Leick, M. B., Mount, C. W., Balaj, L., Nikiforow, S., Carter, B. S., Curry, W. T., Gallagher, K., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2314390 · Cited by 453
González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., Bellet, E., Oaknin, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.011 · Cited by 449
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Wei, J., Long, L., Zheng, W., Dhungana, Y., Lim, S. A., Guy, C., Wang, Y., Wang, Y.-D., Qian, C., Xu, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1821-z · Cited by 447
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors
Tang, N., Cheng, C., Zhang, X., Qiao, M., Li, N., Mu, W., Wei, X.-F., Han, W., & Wang, H. (2020) · JCI Insight · doi:10.1172/jci.insight.133977 · Cited by 413
Caruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 397
Xu, J., Chen, L.-J., Yang, S.-S., Sun, Y., Wu, W., Liu, Y.-F., Xu, J., Zhuang, Y., Zhang, W., Weng, X.-Q., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819745116 · Cited by 390
Bagley, S. J., Logun, M., Fraietta, J. A., Wang, X., Desai, A. S., Bagley, L. J., Nabavizadeh, A., Jarocha, D., Martins, R., Maloney, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02893-z · Cited by 381
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Zhang, J., Hu, Y., Yang, J., Li, W., Zhang, M., Wang, Q., Zhang, L., Wei, G., Tian, Y., Zhao, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05140-y · Cited by 371
Self-citationBATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells
Seo, H., González-Avalos, E., Zhang, W., Ramchandani, P., Yang, C., Lio, C.-W. J., Rao, A., & Hogan, P. G. (2021) · Nature Immunology · doi:10.1038/s41590-021-00964-8 · Cited by 350
Brown, C. E., Hibbard, J. C., Alizadeh, D., Blanchard, M. S., Natri, H. M., Wang, D., Ostberg, J. R., Aguilar, B., Wagner, J. R., Paul, J. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02875-1 · Cited by 345
Co-opting signalling molecules enables logic-gated control of CAR T cells
Tousley, A. M., Rotiroti, M. C., Labanieh, L., Rysavy, L. W., Kim, W.-J., Lareau, C., Sotillo, E., Weber, E. W., Rietberg, S. P., Dalton, G. N., et al. (2023) · Nature · doi:10.1038/s41586-023-05778-2 · Cited by 321
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Wang, X., Wu, X., Tan, B., Zhu, L., Zhang, Y., Lin, L., Xiao, Y., Sun, A., Wan, X., Liu, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.027 · Cited by 320
Self-citationCAR-T cell manufacturing: Major process parameters and next-generation strategies
Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20230903 · Cited by 303
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01128-9 · Cited by 301
Self-citationZhao, Y., Chen, J., Andreatta, M., Feng, B., Xie, Y.-Q., Wenes, M., Wang, Y., Gao, M., Hu, X., Romero, P., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02060-8 · Cited by 299
Mackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Borchmann, P., Heudobler, D., Ferstl, B., Klobuch, S., Bokemeyer, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02612-0 · Cited by 297
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A. B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., et al. (2025) · Nature · doi:10.1038/s41586-024-08261-8 · Cited by 289
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E., Ma, Y., Lu, W., Peng, S., Wang, C. L., et al. (2023) · Nature · doi:10.1038/s41586-022-05531-1 · Cited by 285
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Wang, Z., Li, N., Feng, K., Chen, M., Zhang, Y., Liu, Y., Yang, Q., Nie, J., Tang, N., Zhang, X., et al. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00749-x · Cited by 265
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
LaFleur, M. W., Nguyen, T. H., Coxe, M. A., Miller, B. C., Yates, K. B., Gillis, J. E., Sen, D. R., Gaudiano, E. F., Al Abosy, R., Freeman, G. J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0480-4 · Cited by 245
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
Chan, J. D., Scheffler, C. M., Munoz, I., Sek, K., Lee, J. N., Huang, Y.-K., Yap, K. M., Saw, N. Y. L., Li, J., Chen, A. X. Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07242-1 · Cited by 244
RASA2 ablation in T cells boosts antigen sensitivity and long-term function
Carnevale, J., Shifrut, E., Kale, N., Nyberg, W. A., Blaeschke, F., Chen, Y. Y., Li, Z., Bapat, S. P., Diolaiti, M. E., O’Leary, P., et al. (2022) · Nature · doi:10.1038/s41586-022-05126-w · Cited by 239
Wang, Y., Tong, C., Dai, H., Wu, Z., Han, X., Guo, Y., Chen, D., Wei, J., Ti, D., Liu, Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20696-x · Cited by 234
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Giuffrida, L., Sek, K., Henderson, M. A., Lai, J., Chen, A. X. Y., Meyran, D., Todd, K. L., Petley, E. V., Mardiana, S., Mølck, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23331-5 · Cited by 226
Hirabayashi, K., Du, H., Xu, Y., Shou, P., Zhou, X., Fucá, G., Landoni, E., Sun, C., Chen, Y., Savoldo, B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00244-2 · Cited by 225
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Monje, M., Mahdi, J., Majzner, R., Yeom, K. W., Schultz, L. M., Richards, R. M., Barsan, V., Song, K.-W., Kamens, J., Baggott, C., et al. (2025) · Nature · doi:10.1038/s41586-024-08171-9 · Cited by 225
FOXO1 is a master regulator of memory programming in CAR T cells
Doan, A. E., Mueller, K. P., Chen, A. Y., Rouin, G. T., Chen, Y., Daniel, B., Lattin, J., Markovska, M., Mozarsky, B., Arias-Umana, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07300-8 · Cited by 223
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01170-7 · Cited by 222
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Qi, C., Liu, C., Gong, J., Liu, D., Wang, X., Zhang, P., Qin, Y., Ge, S., Zhang, M., Peng, Z., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03037-z · Cited by 221
Fine-tuning the CAR spacer improves T-cell potency
Watanabe, N., Bajgain, P., Sukumaran, S., Ansari, S., Heslop, H. E., Rooney, C. M., Brenner, M. K., Leen, A. M., & Vera, J. F. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1253656 · Cited by 203
Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor
Zhang, J., Li, J., Hou, Y., Lin, Y., Zhao, H., Shi, Y., Chen, K., Nian, C., Tang, J., Pan, L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.023 · Cited by 202
Self-citationYe, L., Park, J. J., Peng, L., Yang, Q., Chow, R. D., Dong, M. B., Lam, S. Z., Guo, J., Tang, E., Zhang, Y., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.009 · Cited by 201
Liu, G., Rui, W., Zheng, H., Huang, D., Yu, F., Zhang, Y., Dong, J., Zhao, X., & Lin, X. (2020) · European Journal of Immunology · doi:10.1002/eji.201948457 · Cited by 197
Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy
Wu, W., Zhou, Q., Masubuchi, T., Shi, X., Li, H., Xu, X., Huang, M., Meng, L., He, X., Zhu, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.018 · Cited by 197
O’Keefe, D. S., Bacich, D. J., Huang, S. S., & Heston, W. D. W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203877 · Cited by 195
Target selection for CAR-T therapy
Wei, J., Han, X., Bo, J., & Han, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0758-x · Cited by 195
Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness
Chen, J., Qiu, S., Li, W., Wang, K., Zhang, Y., Yang, H., Liu, B., Li, G., Li, L., Chen, M., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00789-0 · Cited by 195
A genome-scale screen for synthetic drivers of T cell proliferation
Legut, M., Gajic, Z., Guarino, M., Daniloski, Z., Rahman, J. A., Xue, X., Lu, C., Lu, L., Mimitou, E. P., Hao, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04494-7 · Cited by 181
Labbé, R. P., Vessillier, S., & Rafiq, Q. A. (2021) · Viruses · doi:10.3390/v13081528 · Cited by 175
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies
Gurusamy, D., Henning, A. N., Yamamoto, T. N., Yu, Z., Zacharakis, N., Krishna, S., Kishton, R. J., Vodnala, S. K., Eidizadeh, A., Jia, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.004 · Cited by 172
Zhang, X., Zhang, C., Qiao, M., Cheng, C., Tang, N., Lu, S., Sun, W., Xu, B., Cao, Y., Wei, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.013 · Cited by 172
Inosine induces stemness features in CAR-T cells and enhances potency
Klysz, D. D., Fowler, C., Malipatlolla, M., Stuani, L., Freitas, K. A., Chen, Y., Meier, S., Daniel, B., Sandor, K., Xu, P., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.002 · Cited by 171
Zhang, Y., Zhang, Z., Ding, Y., Fang, Y., Wang, P., Chu, W., Jin, Z., Yang, X., Wang, J., Lou, J., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03613-7 · Cited by 169
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Pal, S. K., Tran, B., Haanen, J. B. A. G., Hurwitz, M. E., Sacher, A., Tannir, N. M., Budde, L. E., Harrison, S. J., Klobuch, S., Patel, S. S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0102 · Cited by 168
Greco, B., Malacarne, V., Girardi, F. D., Scotti, G. M., Manfredi, F., Angelino, E., Sirini, C., Camisa, B., Falcone, L., Moresco, M. A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg3072 · Cited by 167
Enhanced T cell effector activity by targeting the Mediator kinase module
Freitas, K. A., Belk, J. A., Sotillo, E., Quinn, P. J., Ramello, M. C., Malipatlolla, M. B., Dániel, B., Sándor, K., Klysz, D. D., Bjelajac, J. R., et al. (2022) · Science · doi:10.1126/science.abn5647 · Cited by 163
Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors
Liu, Y., Liu, G., Wang, J., Zheng, Z.-Y., Jia, L., Rui, W., Huang, D., Zhou, Z.-X., Zhou, L., Wu, X., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5191 · Cited by 162
Exhaustion of CAR T cells: potential causes and solutions
Kouro, T., Himuro, H., & Sasada, T. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03442-3 · Cited by 157
Wiede, F., Lu, K., Du, X., Liang, S., Hochheiser, K., Dodd, G. T., Goh, P. K., Kearney, C. J., Meyran, D., Beavis, P. A., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2019103637 · Cited by 147
CAR T cell combination therapies to treat cancer
Uslu, U., Castelli, S., & June, C. H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.07.002 · Cited by 144
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer
Feng, B., Bai, Z., Zhou, X., Zhao, Y., Xie, Y., Huang, X., Liu, Y., Enbar, T., Li, R., Wang, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07962-4 · Cited by 144
Marcucci, K. T., Jadlowsky, J. K., Hwang, W., Suhoski, M. M., Gonzalez, V. E., Kulikovskaya, I. M., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.012 · Cited by 138
Yoshikawa, T., Wu, Z., Inoue, S., Kasuya, H., Matsushita, H., Takahashi, Y., Kuroda, H., Hosoda, W., Suzuki, S., & Kagoya, Y. (2021) · Blood · doi:10.1182/blood.2021012714 · Cited by 135
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Bai, Z., Feng, B., McClory, S., de Oliveira, B. C., Diorio, C. J., Grégoire, C., Tao, B., Yang, L., Zhao, Z., Peng, L., et al. (2024) · Nature · doi:10.1038/s41586-024-07762-w · Cited by 135
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 134
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
Liu, Z., Zhou, J., Yang, X., Liu, Y., Zou, C., Lv, W., Chen, C., Cheng, K. K. Y., Chen, T., Chang, L., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01711-9 · Cited by 134
Nutrient-driven histone code determines exhausted CD8 + T cell fates
Ma, S., Dahabieh, M. S., Mann, T. H., Zhao, S., McDonald, B., Song, W., Chung, H., Farsakoglu, Y., Garcia-Rivera, L., Hoffmann, F. A., et al. (2024) · Science · doi:10.1126/science.adj3020 · Cited by 131
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity
Lynn, R. C., Feng, Y., Schutsky, K., Poussin, M., Kalota, A., Dimitrov, D. S., & Powell, D. J., Jr. (2016) · Leukemia · doi:10.1038/leu.2016.35 · Cited by 122
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
Zhang, B., Qin, D., Mo, Z., Li, Y., Wei, W., Wang, Y., Wang, W., & Wei, Y.-Q. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5027-4 · Cited by 116
Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy
Kang, T. G., Lan, X., Tian, M., Chen, H., Alli, S., Lim, S.-E., Bhatara, S., Vasandan, A. B., Ward, G., Bentivegna, S., et al. (2024) · Science · doi:10.1126/science.adl4492 · Cited by 110
Applying a clinical lens to animal models of CAR-T cell therapies
Duncan, B. B., Dunbar, C. E., & Ishii, K. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.008 · Cited by 102
Zhu, M., Han, Y., Gu, T., Wang, R. Y., Si, X., Kong, D., Zhao, P., Wang, X., Li, J., Zhai, X., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114065 · Cited by 98
Transgelin 2 guards T cell lipid metabolism and antitumour function
Hwang, S., Awasthi, D., Jeong, J., Sandoval, T. A., Chae, C.-S., Ramos, Y., Chen, T., Falco, M. M., Salvagno, C., Emmanuelli, A., et al. (2024) · Nature · doi:10.1038/s41586-024-08071-y · Cited by 95
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Berasain, C. (2013) · Gut · doi:10.1136/gutjnl-2013-304564 · Cited by 94
Regnase-1, a rapid response ribonuclease regulating inflammation and stress responses
Mao, R., Yang, R., Chen, X., Harhaj, E. W., Wang, X., & Fan, Y. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.70 · Cited by 92
Lin, F. Y. H., Stuckert, A. J., Tat, C. L., White, M., Ruggieri, L., Zhang, H., Mehta, B., Lapteva, N., Mei, Z., Major, A. M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02019 · Cited by 86
Zhang, N., Liu, X., Qin, J., Sun, Y., Xiong, H., Lin, B., Liu, K., Tan, B., Zhang, C., Huang, C., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.015 · Cited by 80
Self-citationCAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization
Qiu, S., Chen, J., Wu, T., Li, L., Wang, G., Wu, H., Song, X., Liu, X., & Wang, H. (2024) · Cell Research · doi:10.1038/s41422-024-00936-1 · Cited by 79
Ahn, T., Bae, E., & Seo, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.004 · Cited by 75
Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors
Zheng, R., Shen, K., Liang, S., Lyu, Y., Zhang, S., Dong, H., Li, Y., Han, Y., Zhao, X., Zhang, Y., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01228-9 · Cited by 74
The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
Hilliard, T. S. (2018) · Cancers · doi:10.3390/cancers10090277 · Cited by 73
Qi, C., Zhang, P., Liu, C., Zhang, J., Zhou, J., Yuan, J., Liu, D., Zhang, M., Gong, J., Wang, X., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02314 · Cited by 63
Self-citationMyeloma CAR-T CRS Management With IL-1R Antagonist Anakinra
Jatiani, S., Aleman, A., Madduri, D., Chari, A., Cho, H. J., Richard, S., Richter, J. R., Brody, J., Jagannath, S., & Parekh, S. S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.04.020 · Cited by 61
Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
Yang, X., Nishimiya, D., Löchte, S., Jude, K. M., Borowska, M. T., Savvides, C. S., Dougan, M. L., Su, L., Zhao, X., Piehler, J., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01567-w · Cited by 60
Zhang, Q., Fu, Q., Cao, W., Wang, H., Xu, X., Huang, J., Zou, A., Zhu, J., Wan, H., Yao, Y., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.16_suppl.4019 · Cited by 60
The BTLA–HVEM axis restricts CAR T cell efficacy in cancer
Guruprasad, P., Carturan, A., Zhang, Y., Cho, J. H., Kumashie, K. G., Patel, R. P., Kim, K.-H., Lee, J.-S., Lee, Y., Kim, J. H., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01847-4 · Cited by 54
CAR-T cell therapy for lung cancer: a promising but challenging future
Zhong, S., Cui, Y., Liu, Q., & Chen, S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.118 · Cited by 53
Xu, X., Chen, H., Ren, Z., Xu, X., Wu, W., Yang, H., Wang, J., Zhang, Y., Zhou, Q., Li, H., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.11.005 · Cited by 51
Zhang, Q., Ding, J., Sun, S., Liu, H., Lü, M., Wei, X., Gao, X., Zhang, X., Fu, Q., & Zheng, J. (2019) · PubMed · Cited by 48
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma
Quintarelli, C., Bufalo, F. D., Ioris, M. A. D., Guercio, M., Algeri, M., Pagliara, D., Silvestris, D. A., Nardo, M. D., Sinibaldi, M., Cecca, S. D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03449-x · Cited by 46
Lee, D., Cho, E. J., Lee, J.-H., Yu, S. J., Kim, Y. J., Yoon, J., Kim, T., Han, S., Oh, D., Im, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3094 · Cited by 44
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology
Kembuan, G. J., Kim, J. Y., Maus, M. V., & Jan, M. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.003 · Cited by 39
Huang, D., Li, Y., Rui, W., Sun, K., Zhou, Z., Lv, X., Li, Y., Chen, J., Zhou, J., Liu, V., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114949 · Cited by 38
Xiang, B., Zhang, M., Li, K., Zhang, Z., Liu, Y., Gao, M., Wang, X., Xiao, X., Sun, Y., He, C. H., et al. (2025) · Nature Immunology · doi:10.1038/s41590-024-02047-w · Cited by 34
Self-citationTomlins, S. A., Khazanov, N. A., Bulen, B. J., Hovelson, D. H., Shreve, M. J., Lamb, L. E., Matrana, M. R., Burkard, M. E., Yang, E. S.-H., Edenfield, W. J., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00243-7 · Cited by 32
Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases
Baker, D., & June, C. H. (2024) · Cell · doi:10.1016/j.cell.2024.07.056 · Cited by 32
Hartley, J., & Abken, H. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1064 · Cited by 31
Vaccine-based immunotherapy and related preclinical models for glioma
Yao, L., Hatami, M., Ma, W., & Skutella, T. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.06.009 · Cited by 30
McKean, M. A., Carabasi, M. H., Stein, M. N., Schweizer, M. T., Luke, J. J., Narayan, V., Parikh, R. A., Pachynski, R. K., Zhang, J., Peddareddigari, V. G. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.094 · Cited by 29
Self-citationShadbad, M. A., Hemmat, N., Shahgoli, V. K., Derakhshani, A., Baradaran, F., Brunetti, O., Fasano, R., Bernardini, R., Silvestris, N., & Baradaran, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788211 · Cited by 23
Boosting CAR T cells with anti-tumor mRNA vaccines
Chehrazi‐Raffle, A., Budde, L. E., & Pal, S. K. (2023) · Nature Medicine · doi:10.1038/s41591-023-02623-x · Cited by 10
Beer, T. M., Logothetis, C., Sharma, P., Gerritsen, W. R., Ezzeddine, R., Fairchild, J. P., Gagnier, P., Chin, K. M., & Cuillerot, J.-M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.tps182 · Cited by 8
GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy
Tan, B., Tu, C., Xiong, H., Xu, Y., Shi, X., Zhang, X., Yang, R., Zhang, N., Lin, B., Liu, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.036 · Cited by 8
Self-citation
Metadata
- Authors
- Du, B., Qin, J., Lin, B., Zhang, J., Li, D., & Liu, M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2025-04
- Volume
- 43
- Issue
- 4
- Pages
- 665-679
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4409412608
- Cited by
- 254
- References
- 133
- FWCI
- 92.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.